Methods and kits for identifying and quantifying storage-induced

Refrigerated storage of red cell concentrates (RCC) for transfusion is associated with the accumulation of various alterations to the red blood cells […]

In vitro tests allowing to identify the potential for mdm2 inhibitors

TP53 mutations are the most frequent mutations in all cancer subtypes and their acquisition are key events leading to the transformation of chronic […]

Methods for increasing fetal hemoglobin content in eukaryotic cells

The clinical severity of ?-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal ?-globin chain […]

Use of the emm antigen as a biomarker of inherited gpi deficiencies

Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that […]

Methods and compositions to determine the quality of red blood cell

The present invention relates to a method for determining the quality of haemoglobin (Hb) during the storage period of red blood cell (RBC) units […]

New biomarkers for diagnosis and treatment monitoring for anemia

The invention relates to the domain of anemia, iron overload and myeloid malignancy. The inventors identify a variant transcript of ERFE specific of […]

Use of il-6 inhibitors for the treatment of acute chest syndrome in

Acute chest syndrome (ACS) is a common and potentially lethal form of acute lung injury in sickle cell disease (SCD). Because pathophysiology remains […]

Anti- protease nexin-1 conformational single domain antibodies and

The present invention relates to anti-protease nexin-1 (PN-1) conformational single domain antibodies and uses thereof in particular in the […]

Correction of beta-thalassemia phenotype by genetically engineered

The present invention relates to a genetically modified hematopoietic stem cellrn(HSC) comprising, in at least one ?-globin gene comprised in the […]

Combination of arsenic and interferon alpha for the treatment of

The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a […]